AMGN
Japan just hit the pause button
Amgen’s Japanese partner, Kissei Pharmaceutical, says it’s started information-sharing efforts in Japan and is basically telling doctors: slow your roll on Tavneos. That means avoiding new prescriptions for now and taking a hard look at whether current patients should stay on the drug, given liver-related risks and other treatment options.
The safety cloud keeps getting darker
This isn’t coming out of nowhere. The FDA warned in March about serious and sometimes fatal liver injuries linked to Tavneos, and in April its drug review arm went a step further, proposing to withdraw approval altogether. That’s not exactly the kind of regulatory mood music investors like to hear.
The agency’s concerns went beyond safety, too. It said key data behind the drug’s approval may have been manipulated in the Phase 3 ADVOCATE trial, and it flagged issues with the original application. In other words: this isn’t just a label tweak or a sternly worded note.
Why investors should care
Tavneos is still approved in Japan, but the drumbeat of caution in the U.S., Europe, and now Japan makes the commercial path look messier than a desk drawer full of charging cables.
- More scrutiny can slow uptake
- Doctors may hesitate to start new patients
- Any withdrawal or label change would raise fresh revenue and reputation risk
Big picture: when regulators start comparing notes across continents, biotech investors usually want to sit down and take a deep breath.